WCLC 2023

CME Information

Click on the box below to view the disclosure information for everyone involved in planning or delivering educational content for the IASLC 2023 World Conference on Lung Cancer.

Physicians are entitled to receive a CME certificate after completing the Conference evaluation survey. A link to this survey will be emailed to all attendees at the conclusion of the Conference; the survey can also be accessed from the Conference website. After submitting the survey, physicians have the option to print or save their CME certificate. CME certificates will reflect the number of accredited sessions attended. CME accredited activities are designated in the program guide. The deadline for claiming CME credit is December 31, 2023. Please direct any certificate inquiries to: [email protected].

Non-physicians are entitled to receive a “Certificate of Attendance”. To claim a Certificate of Attendance, non-physicians must first complete the Conference evaluation survey. A survey link will be emailed to all attendees at the conclusion of the Conference; the survey can also be accessed from the Conference website. After submitting the survey, attendees may print or save their Certificate of Attendance. The deadline for receiving a Certificate of Attendance is December 31, 2023. Please direct any certificate inquiries to: [email protected].

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

The International Association for the Study of Lung Cancer designates the “other activity” (a live conference offered in a hybrid format including recorded virtual participation) format for this educational activity for a maximum of 91.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education).

The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.

International CPD Credit Reciprocity Agreements.

The Royal College will recognize the number of participation hours as MOC Program Section 1 accredited group learning credits for group learning activities developed by Accreditation Council for Continuing Medical Education (ACCME)-accredited physician organizations (university, academy, specialty society, hospital department etc.) that are held within and outside of Canada. Agreement dates: November 1, 2019 to December 31, 2025.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

The American Medical Association (AMA) and the Department of Healthcare Professions–Accreditation Section (DHP-AS), Ministry of Public Health–Qatar have renewed their CME agreement under which select activities approved for AMA PRA Category 1 Credit™ are eligible for conversion of the hours of participation to Department of Healthcare Professions Continuing Professional Development (DHP-CPD) credit. This agreement is in place through Dec. 31, 2026.

The International Association for the Study of Lung Cancer (IASLC) complies with the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). IASLC applies these Standards throughout the educational planning process to ensure independence, balance, objectivity and scientific rigor for all Continuing Medical Education (CME) activities.  

In compliance with the ACCME Standards, each individual in a position to control the content of a CME activity is required to disclose all financial relationships with ACCME defined ineligible companies. All disclosures are reviewed to identify relevant financial relationships and any conflicts of interest are mitigated before the individual can assume their role in the activity.  

All disclosures will be available to participants via the Conference website.

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of the IASLC or any company that provided commercial support for this activity.

The IASLC 2023 World Conference on Lung Cancer (WCLC 2023) is the world’s largest international conference for clinicians, researchers and scientists in the field of lung cancer and thoracic oncology. Bringing together lung cancer specialists from around the world and across disciplines, the conference offers opportunities for learning and sharing the latest developments in lung cancer and thoracic malignancy research, prevention, diagnosis, treatment and management. With 20 educational tracks and over 300 global experts as invited speakers, WCLC 2023 provides a robust, comprehensive scientific program encompassing cutting edge knowledge on subjects such as tumor biomarkers, clinical trials, targeted therapies, liquid biopsy, lung cancer screening, immunotherapy, tobacco control and patient advocacy. Sessions include plenaries with live Q&A, expert lectures, panel discussions, oral abstracts and posters.  

The IASLC 2023 World Conference on Lung Cancer is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses and physician assistants. 

At the conclusion of this activity, participants will be able to:  

  1. Examine scientific advances in thoracic cancer including the pathogenesis, biology, and mechanisms of drug interactions that can be used to make evidence-based diagnosis and treatment decisions.
  2. Synthesize cutting edge research from clinical trials and translational studies conducted around the world to deepen knowledge within primary specialty area(s) and broaden knowledge of other specialties.
  3. Support lung cancer prevention strategies including tobacco control, smoking cessation, reducing environmental risks, addressing the quality and value of healthcare, and implementing early screening.
  4. Apply evidence-based recommendations and clinical practice guidelines to diagnose and manage patients.
  5. Employ multidisciplinary teams to improve patient outcomes through patient-centered diagnostic, therapeutic and palliative care.
  6. Support and empower patients to become active participants in their treatment.  

The official language of the IASLC 2023 World Conference on Lung Cancer is English. 


The information presented at the IASLC 2023 World Conference on Lung Cancer is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.  

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.